Antivirus: A weekly digest of COVID-19 research and development
Margaret Keenan, 90, the first patient in the United Kingdom to receive the Pfizer/BioNtech covid-19 vaccine outside of clinical trials gets ready to leave the hospital.
Photo by Jonny Weeks/The Guardian – Pool/Getty Images
When researchers at pharmaceutical companies around the world started developing COVID-19 vaccines, experts reminded everyone to temper expectations. Vaccines usually take years. The frontrunners were made using unproven technology, and there were dozens of ways things could go wrong. The Food and Drug Administration said it would be fine with anything over 50 percent effective.
Then, last month, Pfizer announced that it had a vaccine, and it was 95 percent effective. Moderna did too. It was better news than anyone dared hope for. Stéphane Bancel, chief executive at Moderna, said he cried when he first heard the data. With the FDAs blessing, which came in late Friday night, health care workers in the United States could start getting shots next week, less than a year after the first case of COVID-19 was documented in the country.
Scientists pulled off the impossible thing, and thats worth celebrating. It is a remarkable, awe-inspiring achievement. I would say its miraculous, but calling it a miracle takes away from the work that went into making it possible both over the past few months, and during the years of basic research on coronaviruses and gene-based vaccines.
A newsletter highlighting the COVID-19 research, developments, and stories that matter. Subscribe here!
Were celebrating as much as we are because we need this vaccine to turn the tide of the pandemic. But theres a sad backstory to this party. We only need this vaccine so desperately because the United States failed at doing the hard, basic public health work. Providing contact tracing, ample testing, masks, gloves, and clear policies arent as exciting as the moonshot of a vaccine, but if the US government had done them well, the country wouldnt have been so reliant on the impossible.
Were lucky that the moonshot paid off. There was always a chance it wasnt going to work, and some vaccines have hit serious roadblocks. On Friday, the drug company Sanofi announced a setback it cant start late-stage clinical trials this month, as planned, and its vaccine wont be ready until the second half of 2021. Theres a world where Pfizer and Moderna hit snags, too, or where they didnt work quite as well.
Even though they did work, the development of these vaccines took nearly a year. In that year, hundreds of thousands of people in the US died. They didnt have to. Public health measures are designed to slow the spread of the virus saving lives, and buying scientists time to develop life-saving vaccines. Doing the hard work would have made it so more people could have survived to benefit from them.
Instead, were getting a vaccine just as COVID-19 is surging out of control across the country. Writing in The Atlantic, Juliette Kayyem, former assistant secretary in the Department of Homeland Security, said that the rest of the pandemic would unfold on a split screen. On one side, continuous death and disease. On the other, the start of a vaccination campaign that could keep people safe from the virus. Thursday, an independent committee recommended that the FDA authorize the Pfizer and BioNTech COVID-19 vaccine. That same day, over 3,000 people in the US died from the disease.
Here in the US, were counting down the days before vaccines are widely available, knowing that every day of delay means more illness and more death. Thats not true everywhere. My dad recently told me that he had a meeting with some people living in Australia, and that he asked them what they thought of the vaccine news. Turns out, they didnt really care. Australia controlled the pandemic so well that life is essentially normal it doesnt need a vaccine as an escape hatch. They did the hard thing, so they didnt have to rely on the impossible.
Nicole Wetsman
Heres what else happened this week.
Research
Boston biotech conference led to 245,000 Covid-19 cases across US, genetic fingerprinting showsA Biogen conference in Boston in February was already known to be a superspreader event. But a new study that looks at genetic samples of the virus shows just how bad the aftermath of that event really was. (Maggie Fox, CNN)
Development
COVID-19 vaccine starts working within two weeks after first shotDocuments published by the FDA offered a more detailed window into how the Pfizer/BioNTech vaccine worked. One key finding: the first shot of the vaccine did seem to provide some protection from the virus. (Nicole Wetsman, The Verge)
Australia Scraps Covid-19 Vaccine That Produced H.I.V. False PositivesAustralia canceled its order for an Australian-made vaccine this week. The problem wasnt that the vaccine didnt work it probably did. But it worked by using fragments from a protein found in HIV. Unfortunately, HIV tests were sensitive enough to pick up the antibodies created by the body after patients got the vaccine, resulting in false positives on HIV tests. (Mike Ives/ The New York Times)
New smartphone tool to track side effects of the coronavirus vaccine may be vulnerable to manipulationExperts sounded an early alarm about a tool the CDC plans to use to track side effects of the coronavirus vaccine. They worry it could be easily manipulated. (Lena H. Sun and Isaac Stanley-Becker, The Washington Post)
On the ground, the pledge to vaccinate 20 million against Covid-19 in December seems unrealisticTheres not that much time left in the year, and a whole lot of vaccinations left to distribute. The US lofty goals may not be met by New Years Eve. (Olivia Goldhill, STAT)
Blunders Eroded U.S. Confidence in Early Vaccine Front-RunnerThis is an epic saga of how one promising vaccine candidate made by Oxford and AstraZeneca stumbled badly, pushing it behind candidates produced by competitors Moderna and Pfizer/BioNTech. (Rebecca Robbins, Sharon LaFraniere, Noah Weiland, David D. Kirkpatrick and Benjamin Mueller, New York Times)
Two in U.K. Suffer Allergic Reaction to Pfizers Covid-19 VaccineAs the FDA met to consider whether or not to approve the Pfizer/BioNTech vaccine, regulators in the UK announced that two people had suffered allergic reactions to the vaccine. The regulators said that people with histories of severe allergic reactions should not receive the vaccine. (Joanna Sugden and Bojan Pancevski, The Wall Street Journal)
Sanofi suffers major setback in development of a Covid-19 vaccineSanofis vaccine trial faces a major delay after they discovered that trial participants had been given doses that werent strong enough. The setback delays the vaccines potential deployment by months. (Helen Branswell/STAT)
Perspectives
I push medications to sedate and paralyze them, and then put a tube through their vocal cords. Looking down at them as they go to sleep, Im the last person they see. And for the ones who dont survive, I will have been the only one to hearor rather, not heartheir last words.
Anesthesiologist Kasey Grewe writes for The Atlantic about the grim reality of working in New York hospitals during the spring surge.
When Smiths colleagues couldnt fit a massive piece of equipment through a door at the companys headquarters one summer weekend, rather than wait until Monday to submit a work order to facilities, they found a sledgehammer and knocked down the wall themselves.
James D Walsh writes about one scientists experience working on the Moderna vaccine in Intelligencer.
More than Numbers
To the more than 70,074,860 people worldwide who have tested positive, may your road to recovery be smooth.
To the families and friends of the 1,590,998 people who have died worldwide 294,320 of those in the US your loved ones are not forgotten.
Stay safe, everyone
View all 578 stories